Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report) fell 25.9% during mid-day trading on Thursday . The company traded as low as $0.30 and last traded at $0.30. 753,013 shares were traded during mid-day trading, an increase of 8% from the average session volume of 697,326 shares. The stock had previously closed at $0.41.
Altamira Therapeutics Price Performance
The company’s 50-day simple moving average is $0.40 and its 200 day simple moving average is $0.72.
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Further Reading
- Five stocks we like better than Altamira Therapeutics
- How to Invest in Blue Chip Stocks
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Dividend Capture Strategy: What You Need to Know
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
